Patent · US Active

Pyrrolidine ether derivatives as NK3 receptor antagonists

US8063075B2 · kind B2 · utility

4Cited by

1References

11Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Philippe Jablonski · Steinbrunn-le-Haut, FR
Kenichi Kawasaki · Yokohama, JP
Henner Knust · Rheinfelden (Baden), DE
Anja Limberg · Penzberg, DE
Matthias Nettekoven · Weil am Rhein, DE
Hasane Ratni · Habsheim, FR
Claus Riemer · Glückstadt, DE

Key dates

Filing date	Jun 2, 2009
Grant date	Nov 22, 2011
Priority date	—
Expiry date	Dec 24, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D401/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds of formula Iwherein R1, R2, R3, R′, Ar, m, n, and o are as defined herein. The invention also relates to pharmaceutical compositions containing compounds of formula I and methods for the manufacture of such compounds and compositions. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.